# Recursion Pharmaceuticals, Inc. RXRX

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001601830

**C**

**middle fifth of 305 graded peers in healthcare**

rank 167 of 305; percentile 54.6; sampling error 2.8 points; lower is stronger


A B C D E

**C, the tortoise**




| Scoreboard | |
|---|---|
| **Profitability** | D<br>percentile 70.4 |
| **Solvency** | B/C<br>percentile 38.6 |
| **Growth and financing** | B/C<br>percentile 37.9 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $1.5B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution; fortress balance sheet<br>not computable: distress |
| **Inputs computable** | 8 of 13 |
| **Graded from** | filings received through Feb 25, 2026<br>268 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026 |
| **Last close** | $2.72<br>2026-11-19; market equity $1.7B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 25, 2026*

Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter - faster, better, and at scale - for patients who are waiting.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 70.4** | | | | | | |
| Gross profitability | 0.3% | 32.8% | | 93.6 | 346 | 2025-12-31 |
| Return on invested capital | (151.3%) | 9.6% | | 95.7 | 70 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (18.7%) | (6.7%) | 22.0 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 4* | | | | | |
| **Solvency, sleeve percentile 38.6** | | | | | |
| Altman Z double-prime | (1.13) | 0.31 | 42.9 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *interest expense must exceed $100,000* | | | | | |
| Current ratio | 5.50x | 2.68x | 34.2 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 37.9** | | | | | |
| Revenue growth, three-year compound | 23.3% | 9.6% | 28.3 | 400 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *NOPAT must exceed $100,000* | | | | | |
| Asset growth, three years | 28.1% | 3.2% | 15.9 | 663 | 2025-12-31 |
| Net share issuance, one year | 33.1% | 1.6% | 69.6 | 625 | 2025-12-31 |


## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 33.1% |
| Fortress balance sheet | cash minus debt is 733,730,000 USD; Altman Z is not used |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 162 | RadNet, Inc. (RDNT) | 53.0 | C | |
| 163 | InspireMD, Inc. (NSPR) | 53.3 | C | dilution, short runway |
| 164 | Solventum Corp. (SOLV) | 53.6 | C | |
| 165 | Neuroone Medical Technologies Corp. (NMTC) | 53.9 | C | short runway, fortress balance sheet |
| 166 | Schrodinger, Inc. (SDGR) | 54.3 | C | |
| 167 | Recursion Pharmaceuticals, Inc. (RXRX) | 54.6 | C | dilution, fortress balance sheet |
| 168 | Haemonetics Corp. (HAE) | 54.9 | C | |
| 169 | Lensar, Inc. (LNSR) | 55.3 | C | |
| 170 | Universal Health Services Inc. (UHS) | 55.6 | C | |
| 171 | Aveanna Healthcare Holdings, Inc. (AVAH) | 55.9 | C | |
| 172 | Nexgel, Inc. (NXGL) | 56.2 | C | late filer |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (25.2%) | (1.7%) | 33 |
| Distance from 52-week high | (45.2%) | (31.7%) | 37 |
| EBIT to enterprise value | (56.6%) | 0.5% | 12 |
| Free cash flow yield | (22.3%) | 0.6% | 20 |
| Book value to price | 0.53 | 0.29 | 69 |
| Sales to price | 0.04 | 0.37 | 9 |
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | (0.46) | (0.19) | 33 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 4 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $549.9M |
| Operating cash flow, four quarters | -$310.5M |
| Months of runway | 21.2 |
| Days since last periodic filing | 18 (10-Q received Nov 2, 2026) |
| Median daily dollar volume, 63 sessions | $76.5M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $74.7M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $71.0M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 3 | assets | us-gaap:Assets | $1.5B | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 4 | operating income | us-gaap:OperatingIncomeLoss | -$648.1M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$644.9M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$136,000 | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 7 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $9.6M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 8 | book equity | us-gaap:StockholdersEquity | $1.1B | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $743.3M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 10 | total debt | us-gaap:LongTermDebtAndCapitalLeaseObligations | $19.0M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 11 | book equity | us-gaap:StockholdersEquity | $1.0B | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 12 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $594.4M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 13 | net income | us-gaap:NetIncomeLoss | -$644.8M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$371.8M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 15 | assets | us-gaap:Assets | $1.4B | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 16 | current assets | us-gaap:AssetsCurrent | $812.8M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $147.7M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 18 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$2.1B | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 19 | liabilities | us-gaap:Liabilities | $343.3M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 20 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $83.7M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | -$350.1M | 2023-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 22 | interest expense | us-gaap:InterestExpense | $97,000 | 2023-12-31 | 2024-02-29 | 10-K | 24-000019 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $58.8M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 24 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $44.6M | 2023-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 25 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $39.8M | 2022-12-31 | 2025-02-28 | 10-K | 25-000035 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.5M | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$359.2M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $13.7M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$287.8M | 2023-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $12.0M | 2023-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$83.5M | 2022-12-31 | 2025-02-28 | 10-K | 25-000035 |
| 32 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $37.1M | 2022-12-31 | 2025-02-28 | 10-K | 25-000035 |
| 33 | current assets | us-gaap:AssetsCurrent | $714.3M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $187.5M | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 35 | assets | us-gaap:Assets | $653.7M | 2023-12-31 | 2025-02-28 | 10-K | 25-000035 |
| 36 | assets | us-gaap:Assets | $701.3M | 2022-12-31 | 2024-02-29 | 10-K | 24-000019 |
| 37 | shares outstanding | us-gaap:CommonStockSharesOutstanding | 528,182,693 | 2025-12-31 | 2026-02-25 | 10-K | 26-000039 |
| 38 | shares outstanding | us-gaap:CommonStockSharesOutstanding | 396,802,394 | 2024-12-31 | 2026-02-25 | 10-K | 26-000039 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.